Kevin M. Friedman - Concepedia

Author

Kevin M. Friedman

National Institutes of Health

Also Known As

Friedman, Kevin M., K. Friedman, Kevin Friedman, Kevin M Friedman, Kevin M. Friedman

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

National Institutes of Health National Cancer Institute Bluebird Bio (United States)Sarah Cannon Massachusetts General Hospital

About

Kevin M. Friedman is an author at National Institutes of Health specializing in medicine, cell biology, and tumor microenvironment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	528
2	Cell Biology	5	5	528
3	Cellular Therapies	2	2	123
4	Natural Sciences	1	1	54
5	Biochemistry	1	1	54

Kevin M. Friedman

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma Noopur Raje, Jesús G. Berdeja, Yi Lin, New England Journal of Medicine	2019	1.7K
Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells Kevin M. Friedman, Tracy E. Garrett, John Evans, Human Gene Therapy Lymphocyte DevelopmentAdaptive Immune SystemImmunologyImmunoeditingImmunodominance	2018	203
Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway Rasha Abu Eid, Raed Samara, Laurent Ozbun, Cancer Immunology Research Pi3k InhibitorsT-regulatory CellImmune RegulationImmunologyTreg Depletion	2014	148
Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes Kevin M. Friedman, Peter A. Prieto, Laura Devillier, Journal of Immunotherapy Specific ReactivityCell TherapyImmunologyImmunoeditingImmunotherapeutics	2012	102
The ISG15 Isopeptidase UBP43 Is Regulated by Proteolysis via the SCFSkp2 Ubiquitin Ligase Sara Tokarz, Catherine Berset, Janna La Rue, Journal of Biological Chemistry Type 1Protein FunctionCell RegulationBiochemistryNatural Sciences	2004	54
Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8<sup>+</sup>T-cell proliferation and survival Rasha Abu Eid, Kevin M. Friedman, Mikayel Mkrtichyan, OncoImmunology	2015	49
Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells Molly Perkins, Shannon Grande, Amanda Hamel, Blood	2015	26
Augmented Lymphocyte Expansion from Solid Tumors With Engineered Cells for Costimulatory Enhancement Kevin M. Friedman, Laura Devillier, Steven A. Feldman, Journal of Immunotherapy Cell TherapyTil GenerationImmunologyBiological MicroenvironmentsImmunoediting	2011	21
Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy Olivia Finney, Ashish Yeri, Pingping Mao, Blood	2020	17

Page 1